Navigation Links
Labopharm Reports Results for Third Quarter Fiscal 2007
Date:11/9/2007

in the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become a fully integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

For the: Three months ended Nine months ended

Sept 30, Sept 30, Sept 30, Sept 30,

2007 2006 2007 2006

(Thousands of Canadian

do
'/>"/>

SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Last week, the Fed reported an ... Industrial production rose to 0.4% while manufacturing output progressed to ... single largest boost since February this year. Capacity use has ... as well – an increase that could be attributed to ... 79.2% rate, which is a measure of slack across the ...
(Date:8/29/2014)... India (PRWEB) August 29, 2014 Ethane ... has recently launched a new service named HTML web ... research based service. Before tailoring the service, Ethane Web ... by other companies. The company has done its best ... impeccable and able to deliver outstanding results to clients. ...
(Date:8/29/2014)... effect, stimulating neurite extension in the presence ... enhancing nerve regeneration following nerve crush injury ... to stimulate nerve regeneration is limited because ... hypertension, and its considerable cost. With long-term ... drugs reportedly cause life-threatening infections. Like FK506, ...
(Date:8/29/2014)... The Fresh Diet, America’s premier gourmet meal delivery ... meal plan. Originating from The Fresh Diet’s commitment to ... designed to satisfy customers seeking a convenient, worry-free option ... to the growing demand by customers for non-meat menu ... with 14% of Americans identifying vegetarian meals as ‘more ...
(Date:8/29/2014)... 2014 Glendale Botox experts at ... Botox throughout the month of September. This special offer features ... syringes of Juvederm. Patients can take advantage of this special ... Glendale Botox experts will work with patients to determine if ... What is Botox? , Botox is a treatment made ...
Breaking Medicine News(10 mins):Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 3Health News:Ethane Web Technologies Launches a New Web Design Service 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 3Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2
... New personalized service educates clients about Medicare; identifies best options ... , ... Belleville, Ill. (Vocus) September 10, ... expanding the services it offers to individuals with disabilities with ...
... PARSIPPANY, N.J., Sept. 10 DSM Pharmaceutical ... Nice LLC as agency of,record for marketing ... covers services for this DSM business group ... DSM Biologics and DSM Pharmaceuticals, Inc., ...
... 10, 2008)In recent years, private equity investors have ... by investigative reports and anecdotal evidence that these ... companies have found themselves under increased federal scrutiny. ... such conclusions may be premature. Private equity purchases ...
... and C14-UBT are the most commonly used non-invasive tests of ... tests depend also on the prevalence of H. pylori ... the tests depend also on the prevalence of H. ... imply higher sensitivity and lower specificity. There are reports suggesting ...
... for people who support affordable health insurance options for American ... ... politicians dispense,their health care ideas at party conventions and local rallies, ... to do so is at,AffordableHealthInsurance.NET -- a new social network that ...
... Inc.,(Nasdaq: ENCO ), a full service multinational ... countries for many of the world,s,leading pharmaceutical and ... an amendment (the "Amendment") to its letter of ... the,Amendment, the Company will acquire all of the ...
Cached Medicine News:Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 2Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 3Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 4Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 5Health News:DSM Pharmaceutical Products Announces the Appointment of That's Nice LLC as Agency of Record for Marketing 2Health News:DSM Pharmaceutical Products Announces the Appointment of That's Nice LLC as Agency of Record for Marketing 3Health News:Private equity companies purchase nursing homes, but care does not suffer 2Health News:Private equity companies purchase nursing homes, but care does not suffer 3Health News:Social Network for Affordable Health Care Supporters Stimulates a New Level of Interactivity and Dialogue 2Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 2Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 3Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 4Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 5
(Date:8/29/2014)... -- Diseases largely eradicated in the United ... was declared eliminated in 2000, yet the CDC reports ... highest incidence in 20 years. In July, ... a problem of "epidemic proportions." ... these preventable diseases—in part because some parents (more than ...
(Date:8/29/2014)... YORK, Pa. , Aug. 29, 2014  Unilife ...  ASX: UNS) announced today that it intends to release ... and year ended June 30, 2014 after market trading ... Management has scheduled a conference call for 4:30 p.m. ... 10, 2014 at 6:30 a.m. AEST), to review the Company,s ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present ... Australian and New Zealand Forensic Science Society,s 22 ... in Adelaide, Australia .  Forensic ... the advancements that hyperspectral imaging can bring to ... Beckstead , Director of Product Development at ChemImage, ...
Breaking Medicine Technology:Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... Anthera Pharmaceuticals,announced today they have reached agreement ... on a Phase 3 protocol for varespladib ... FDA,s Special Protocol Assessment,procedure. At the same ... European Medicines Agency (EMEA) on Anthera,s European ...
... Summary: Genmab has Completed Recruitment of Patients in the ... of Ofatumumab in Rituximab Refractory Follicular NHL, COPENHAGEN, ... has completed recruitment of patients in the,pivotal Phase III ... (NHL). Eighty-one patients,receiving treatment at the 1000 mg dose ...
Cached Medicine Technology:Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval 2Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval 3Recruitment Completed in Ofatumumab NHL Pivotal Study 2Recruitment Completed in Ofatumumab NHL Pivotal Study 3